abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

ITGA2&ITGB1
Back
Total number of drugs
5
Phase II and later clinical stages
0%
Involving companies
4
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
PA-0661PA-0661Monoclonal antibodyNeoplasms Skin and Musculoskeletal DiseasesCadherin 5 inhibitors Integrin alpha2/beta1 agonistsProtein Alternatives SLProtein Alternatives SLPreclinicalPA-0661
detail  >
BTT-3033BTT-3033Small molecule drugIntegrin alpha2/beta1 antagonistsBiotie Therapies OyDiscontinuedBTT-3033
detail  >
BTT-3034BTT-3034Small molecule drugIntegrin alpha2/beta1 antagonistsBiotie Therapies OyDiscontinuedBTT-3034
detail  >
EMS-16EMS-16Small molecule drugNeoplasmsIntegrin alpha2/beta1 antagonistsBiogen, Inc.DiscontinuedEMS-16
detail  >
Integrin α2β1 regulates(University of California San Francisco)Integrin α2β1 regulates(University of California San Francisco)Small molecule drugImmune System Diseases Respiratory DiseasesIntegrin alpha2/beta1 antagonistsThe University of California, San FranciscoPreclinicalIntegrin α2β1 regulates(University of California San Francisco)
detail  >
Total 5 data
1